BillionToOne Q3 revenue $83.5M (+117% YoY); guides FY2025 revenue $293-299M

BillionToOne, Inc.

Q3 total revenue $83.5M (+117% YoY); prenatal revenue $74.1M (+102%), oncology $8.7M (7.6x YoY).
GAAP operating income of $9.6M vs. ($12.6M) loss YoY; net income $1.5M ($0.10 diluted EPS).
Gross margin improved to 70% from 53% YoY; tests delivered up 52% to 165,000; ASP up 44% to $501.
Guides FY2025 revenue $293-299M (93-96% growth); expects positive operating income for Q4 and full year.
Appointed Anthony Pagano (Genmab CFO) as Audit Committee Chair, effective Jan 1, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.